Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Francesca Barone Sells 13,673 Shares of Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Francesca Barone sold 13,673 shares of the business’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $8.22, for a total transaction of $112,392.06. Following the completion of the sale, the insider now directly owns 124,207 shares in the company, valued at approximately $1,020,981.54. This represents a 9.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Candel Therapeutics Stock Down 6.3 %

CADL stock opened at $8.18 on Friday. The company has a market cap of $265.65 million, a price-to-earnings ratio of -4.73 and a beta of -1.20. Candel Therapeutics, Inc. has a twelve month low of $1.16 and a twelve month high of $14.60. The business has a 50 day moving average price of $6.37 and a two-hundred day moving average price of $6.22. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 1.66.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $19.00 price target (up from $11.00) on shares of Candel Therapeutics in a research note on Wednesday, December 18th.

Hedge Funds Weigh In On Candel Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC bought a new stake in Candel Therapeutics during the third quarter worth $46,000. Geode Capital Management LLC raised its holdings in shares of Candel Therapeutics by 12.8% in the 3rd quarter. Geode Capital Management LLC now owns 448,997 shares of the company’s stock valued at $3,112,000 after purchasing an additional 51,111 shares during the period. State Street Corp lifted its stake in Candel Therapeutics by 4.1% in the 3rd quarter. State Street Corp now owns 492,005 shares of the company’s stock valued at $3,410,000 after purchasing an additional 19,207 shares during the last quarter. Barclays PLC lifted its stake in Candel Therapeutics by 327.1% in the 3rd quarter. Barclays PLC now owns 28,688 shares of the company’s stock valued at $199,000 after purchasing an additional 21,971 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Candel Therapeutics during the second quarter worth about $162,000. 13.93% of the stock is owned by institutional investors.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.